Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG: 3613)
Hong Kong
· Delayed Price · Currency is HKD 7.36
-0.14 (-1.87%)
Sep 9, 2024, 11:35 AM HKT
Beijing Tong Ren Tang Chinese Medicine Company Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,377 | 1,525 | 1,731 | 1,556 | 1,315 | 1,433 | Upgrade
|
| Revenue Growth (YoY) | -28.21% | -11.91% | 11.24% | 18.31% | -8.19% | -5.37% | Upgrade
|
| Cost of Revenue | 384.69 | 477.7 | 580.96 | 436.54 | 362.44 | 419.84 | Upgrade
|
| Gross Profit | 991.96 | 1,047 | 1,150 | 1,120 | 952.9 | 1,013 | Upgrade
|
| Selling, General & Admin | 426.99 | 410.29 | 341.68 | 341.68 | 307.81 | 363.92 | Upgrade
|
| Other Operating Expenses | -7.49 | -6.53 | -2.51 | -1.71 | -1.91 | -3.11 | Upgrade
|
| Operating Expenses | 440.82 | 424.95 | 345.65 | 347.49 | 309.23 | 360.81 | Upgrade
|
| Operating Income | 551.14 | 622.3 | 804.49 | 772.13 | 643.67 | 651.99 | Upgrade
|
| Interest Expense | -6.53 | -5.98 | -4.66 | -4.71 | -4.3 | -4.21 | Upgrade
|
| Interest & Investment Income | 78.86 | 72.88 | 20.59 | 4.38 | 21.65 | 43.42 | Upgrade
|
| Earnings From Equity Investments | -7.86 | -3.26 | -1.54 | 0.26 | -0.86 | -1.97 | Upgrade
|
| EBT Excluding Unusual Items | 615.61 | 685.94 | 818.88 | 772.06 | 660.16 | 689.22 | Upgrade
|
| Other Unusual Items | 1.85 | 1.85 | 7.09 | 6.33 | 25.73 | - | Upgrade
|
| Pretax Income | 617.46 | 687.79 | 825.96 | 778.39 | 685.9 | 689.22 | Upgrade
|
| Income Tax Expense | 84.4 | 97.2 | 134.67 | 126.85 | 118.01 | 112.37 | Upgrade
|
| Earnings From Continuing Operations | 533.06 | 590.59 | 691.29 | 651.54 | 567.88 | 576.85 | Upgrade
|
| Minority Interest in Earnings | -38.93 | -50.19 | -45.42 | -43.71 | -25.43 | -20.73 | Upgrade
|
| Net Income | 494.14 | 540.39 | 645.88 | 607.84 | 542.46 | 556.12 | Upgrade
|
| Net Income to Common | 494.14 | 540.39 | 645.88 | 607.84 | 542.46 | 556.12 | Upgrade
|
| Net Income Growth | -29.13% | -16.33% | 6.26% | 12.05% | -2.46% | -4.24% | Upgrade
|
| Shares Outstanding (Basic) | 837 | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| Shares Outstanding (Diluted) | 837 | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| EPS (Basic) | 0.59 | 0.65 | 0.77 | 0.73 | 0.65 | 0.66 | Upgrade
|
| EPS (Diluted) | 0.59 | 0.65 | 0.77 | 0.73 | 0.65 | 0.66 | Upgrade
|
| EPS Growth | -29.13% | -16.33% | 6.26% | 12.05% | -2.46% | -4.24% | Upgrade
|
| Free Cash Flow | -383.63 | 438.97 | 508.94 | 753.74 | 103.17 | 534.02 | Upgrade
|
| Free Cash Flow Per Share | -0.46 | 0.52 | 0.61 | 0.90 | 0.12 | 0.64 | Upgrade
|
| Dividend Per Share | 0.330 | 0.330 | 0.330 | 0.280 | 0.240 | 0.230 | Upgrade
|
| Dividend Growth | 0% | 0% | 17.86% | 16.67% | 4.35% | 0% | Upgrade
|
| Gross Margin | 72.06% | 68.67% | 66.44% | 71.95% | 72.44% | 70.69% | Upgrade
|
| Operating Margin | 40.03% | 40.81% | 46.47% | 49.62% | 48.94% | 45.51% | Upgrade
|
| Profit Margin | 35.89% | 35.44% | 37.31% | 39.06% | 41.24% | 38.82% | Upgrade
|
| Free Cash Flow Margin | -27.87% | 28.79% | 29.40% | 48.44% | 7.84% | 37.28% | Upgrade
|
| EBITDA | 568.07 | 638.96 | 818.84 | 786.5 | 666.2 | 679.92 | Upgrade
|
| EBITDA Margin | 41.26% | 41.90% | 47.30% | 50.54% | 50.65% | 47.46% | Upgrade
|
| D&A For EBITDA | 16.92 | 16.66 | 14.35 | 14.37 | 22.53 | 27.93 | Upgrade
|
| EBIT | 551.14 | 622.3 | 804.49 | 772.13 | 643.67 | 651.99 | Upgrade
|
| EBIT Margin | 40.03% | 40.81% | 46.47% | 49.62% | 48.94% | 45.51% | Upgrade
|
| Effective Tax Rate | 13.67% | 14.13% | 16.30% | 16.30% | 17.21% | 16.30% | Upgrade
|
| Advertising Expenses | - | 47.39 | 19.18 | 23.58 | 16.82 | 12.35 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.